Reuters -- A U.S. panel dealt a blow to Roche Holding AG’s (ROG.VX) multibillion-dollar cancer drug Avastin on Tuesday, urging U.S. officials to revoke the medicine’s approval for breast cancer after concluding studies showed insufficient benefit for patients.
